Suppr超能文献

长效注射用帕利哌酮棕榈酸酯治疗精神分裂症的卫生经济学研究:中国为期一年的镜像研究。

A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China.

机构信息

Shandong Mental Health Center, No.49 Wenhua East Road, 250014, Jinan, Shandong, People's Republic of China.

出版信息

BMC Psychiatry. 2022 Feb 8;22(1):95. doi: 10.1186/s12888-022-03728-2.

Abstract

Schizophrenia is ranked among the top 25 leading causes of disability worldwide in 2013 which resulting in social and economic burden. By observing patients with schizophrenia one year before and after switching from oral antipsychotics (OAPs) to once-monthly paliperidone palmitate (PP1M), we can better understand the change of total costs in schizophrenic patients, including direct costs and indirect costs, after switching treatment patterns.A total of 100 schizophrenic (ICD-10) patients from Shandong Mental Health Center were collected from December 2016 to June 2019. Treatment modalities, health care resource utilization and costs were compared before and after switching directly from oral antipsychotics to PP1M.Of the 82 patients included in the main analyses, treatment with PP1M resulted in an increase in direct costs of 31.92% (P < 0.01), an increase in medicine costs of approximately 142% (P < 0.01), and a reduction in hospital costs of 68.15% (P > 0.05). There was no significant increase in total costs (P = 0.25), while 31.92% increase in direct costs (P < 0.01), and 35.62% decrease in indirect costs (P < 0.01) after conversion to PP1M. Compared with before administration of PP1M, patients with ≥ 1 inpatient stay in 1 year Pre-PP1M treatment with OAPs (n = 32) had a 20.16% decrease in direct costs (P < 0.01), a 144% increase in medicine costs (P < 0.01), and a significant 72.02% decrease in hospital costs (P < 0.01). The observed reduction in the number of hospitalizations (t = 2.56, P ≤ 0.01) and inpatient stays (t = 1.73, P < 0.05) and after transition to PP1M resulted in a reduction in hospitalization costs (P < 0.01).Switching from OAPs to PP1M decreased the household workforce burden without increasing clinical healthcare costs. Direct costs were significantly reduced in patients with ≥ 1 inpatient stay in 1 year pre-PP1M treatment with OAPs after the switch, which decreased by improving adherence to therapy and reducing the number and length of hospital stays, suggesting that those patients may benefit after switching to PP1M.

摘要

精神分裂症在 2013 年全球 25 大致残原因中排名靠前,导致社会和经济负担沉重。通过观察精神分裂症患者在从口服抗精神病药物(OAPs)转换为每月一次的棕榈酸帕利哌酮(PP1M)前后一年的情况,我们可以更好地了解精神分裂症患者在治疗模式转换后总费用的变化,包括直接费用和间接费用。

2016 年 12 月至 2019 年 6 月,从山东省精神卫生中心共收集了 100 例精神分裂症(ICD-10)患者。比较了直接从口服抗精神病药转换为 PP1M 前后的治疗方式、卫生资源利用和成本。

在主要分析中,82 例患者中有 31.92%(P<0.01)的直接成本增加,药物成本增加约 142%(P<0.01),而住院费用减少 68.15%(P>0.05)。总费用没有显著增加(P=0.25),但直接费用增加 31.92%(P<0.01),间接费用减少 35.62%(P<0.01)。与使用 PP1M 之前相比,在 OAPs 治疗的 1 年 Pre-PP1M 期间有≥1 次住院治疗的患者(n=32)直接费用降低 20.16%(P<0.01),药物费用增加 144%(P<0.01),住院费用显著降低 72.02%(P<0.01)。观察到的住院次数(t=2.56,P≤0.01)和住院天数(t=1.73,P<0.05)减少,以及在转换为 PP1M 后住院费用减少(P<0.01)。

从 OAPs 转换为 PP1M 降低了家庭劳动力负担,而没有增加临床医疗保健成本。在 OAPs 治疗的 1 年 Pre-PP1M 期间有≥1 次住院治疗的患者在转换后直接费用显著降低,这是通过提高治疗依从性和减少住院次数和住院时间来实现的,这表明这些患者在转换为 PP1M 后可能受益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/269c/8827182/662dc94bf3dc/12888_2022_3728_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验